Skip to main content

Table 2 Subgroup analysis of pooled estimates for the mean plasma tHcy in the cases compared with the controls

From: Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis

Subgroup

Studies (n)

WMD (95%CI)

Test for overall effect

Study heterogeneity

P for meta-regression

    

χ2

P

I2

 

Overnight fast

      

0.269

Yes

28

2.41 (1.41, 3.41)

Z =4.71, P <0.001

481.24

<0.001

94.4%

 

No

7

1.20 (0.25, 2.16)

Z =2.46, P =0.014

23.70

0.001

74.7%

 

Diagnosis

      

0.343

RVOa

18

2.56 (1.39, 3.72)

Z =4.31, P <0.001

222.86

<0.001

92.4%

 

CRVO

17

1.67 (0.39, 3.00)

Z =2.55, P =0.011

314.88

<0.001

94.9%

 

Source of cases

      

0.696

Hospital records

9

1.60 (0.47, 2.74)

Z =2.76, P =0.006

52.86

<0.001

84.9%

 

Consecutive patients

26

2.24 (1.25, 3.23)

Z =4.44, P <0.001

401.13

<0.001

93.8%

 

Adjusting factors

      

0.245

NA

1

4.30 (3.80, 4.80)

Z =17.00, P <0.001

-

-

-

 

Age

10

1.33 (0.47, 2.18)

Z =3.05, P =0.002

32.23

<0.001

72.1%

 

Age, sex

24

2.34 (1.19, 3.50)

Z =3.98, P <0.001

409.41

<0.001

94.4%

 
  1. aRVO subgroup includes CRVO, BRVO and others (e.g., hemi-retinal, hemispheric, macular).
  2. tHcy = total homocysteine; WMD = weighted mean differences; CI = confidence interval; RVO = retinal vein occlusion; CRVO = central retinal vein occlusion.